The underlying pathophysiology following traumatic brain injury (TBI) in how different neurodegenerative conditions are developed are still unknown. Different neuroinflammatory and neurodegenerative pathways have been suggested. The goal of this study is to follow-up patients that have been treated for TBI at the neurosurgical department about 10-15 years after their initial injury, in order to analyze fluid biomarkers of inflammation, injury and degeneration and associate these with structural imaging and long-term functional outcome. The investigators aim to invite about 100 patients back and perform advanced magnetic resonance imaging protocols, sample cerebrospinal fluid and blood for different bio- and inflammatory markers, study genetic modifications and associate it with outcomes being assessed through questionnaires. The investigators' hypothesis is that patients with ongoing inflammatory processes will present with more fluid biomarkers of neurodegeneration, worse clinical presentation and also more structural/atrophic signs on imaging. This will result in an increased understanding of the interplay between neuroinflammation and neurodegeneration in chronic TBI, as well as a panel of tentative biomarkers that could be used to assess level of disability following TBI and chronic traumatic encephalopathy (CTE).
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
GOSE vs structural outcome
Timeframe: Assessed at the chronic time-point (10-15 years after injury).
Barthel Index vs structural outcome
Timeframe: Assessed at the chronic time-point (10-15 years after injury).
Fatigue Severity Scale vs structural outcome
Timeframe: Assessed at the chronic time-point (10-15 years after injury).
MOCA vs structural outcome
Timeframe: Assessed at the chronic time-point (10-15 years after injury).
SF-36 vs structural outcome
Timeframe: Assessed at the chronic time-point (10-15 years after injury).
EQ-5D vs structural outcome
Timeframe: Assessed at the chronic time-point (10-15 years after injury).
MADRS vs structural outcome
Timeframe: Assessed at the chronic time-point (10-15 years after injury).
Structural outcome vs proteomic markers in serum
Timeframe: Assessed at the chronic time-point (10-15 years after injury).
Structural outcome vs proteomic markers in cerebrospinal fluid
Timeframe: Assessed at the chronic time-point (10-15 years after injury).
Structural outcome vs auto-antibodies in serum
Timeframe: Assessed at the chronic time-point (10-15 years after injury).